循環器ジャーナル71巻4号

2023年10月発行

特集 変革期を迎えた肺高血圧症—次世代の病態理解，診断，治療とは？ Ⅱ.各論：各種肺高血圧症の診断と治療

PAH治療薬①：エンドセリン受容体拮抗薬

著者： 牧尚孝¹

所属機関： ¹自治医科大学附属さいたま医療センター循環器内科

ページ範囲：P.502 - P.509

POINT
●エンドセリンは肺動脈性肺高血圧症を進行させる悪玉因子である．
●エンドセリン受容体拮抗薬は多剤併用により強力な治療効果が得られる．

参考文献

1）Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 ; 332 : 411-5.

2）Bremnes T, Paasche JD, Mehlum A, et al. Regulation and intracellular trafficking pathways of the 318 endothelin receptors. J Biol Chem 2000 ; 275 : 17596-604.

3）Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002 ; 346 : 896-903.

4）Galiè N, Olschewski H, Oudiz R, et al ; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies（ARIES）Group. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy（ARIES）study 1 and 2. Circulation 2008 ; 117 : 3010-9.

5）Pulido T, Adzerikho I, Channick R, et al ; SERAPHIN Investigators. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013 ; 369 : 809-18.

6）Galiè N, Jansa P, Pulido T, et al. SERAPHIN hemodynamic substudy : the effect of the dual endothelin receptor antagonist macitentan on haemodynamic paraeters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension. Eur Heart J 2017 ; 38 : 1147-55.

7）Galiè N, Humbert M, Vachiery JL, et al ; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology（ESC）and the European Respiratory Society（ERS） : Endorsed by : Association for European Paediatric and Congenital Cardiology（AEPC）, International Society for Heart and Lung Transplantation（ISHLT）. Eur Heart J 2016 ; 37 : 67-119.

8）Galie N, Barbera JA, Frost AE, et al ; AMBITION Investigators. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med 2015 ; 373 : 834-44.

9）Sitbon O, Cottin V, Canuet M, et al. Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. Eur Respir J 2020 ; 56 : 2000673.

10）Chin KM, Sitbon O, Doelberg M, et al. Three-Versus Two-Drug Therapy for Patients with Newly Diagnosed Pulmonary Arterial Hypertension. J Am Coll Cardiol 2021 ; 78 : 1393-1403.

11）Humbert M, Kovacs G, Hoeper MM, et al ; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022 ; 43 : 3618-731.

12）日本循環器学会，日本肺高血圧・肺循環学会，日本呼吸器学会，他．肺高血圧症治療ガイドライン（2017年改訂版）．2018　https://www.j-circ.or.jp/cms/wp-content/uploads/2017/10/JCS2017_fukuda_h.pdf（2023年8月閲覧）

13）臨床研究情報ポータルサイト　https://rctportal.niph.go.jp/result（2023年8月閲覧）